-

08:27:45 AM

Latest DVAX Stock Market News

DVAX - Dynavax Technologies Corp.

09/22/21 7:08 AM

Nasdaq : DVAX

clinical trialcovid-19

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Clover Biopharmaceuticals (Clover) reported positive data for their protein-based COVID-19 vaccine

RHEA-AI

neutral

09/13/21 2:30 AM

Nasdaq : DVAX

covid-19

Dynavax Provides Update on its COVID-19 Collaboration with Valneva

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Valneva SE has received a termination notice from the United Kingdom Government in relation to

RHEA-AI

positive

09/09/21 4:02 PM

Nasdaq : DVAX

conferences

Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global

RHEA-AI

neutral

09/02/21 4:02 PM

Nasdaq : DVAX

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 224,000 shares of Dynavax common stock as inducements to 8 newly-hired employees in connection with

RHEA-AI

very positive

08/23/21 8:00 AM

Nasdaq : DVAX

covid-19

Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant

Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies Corporation (Nasdaq: DVAX), a

RHEA-AI

positive

08/04/21 4:02 PM

Nasdaq : DVAX

earnings

Dynavax Announces Second Quarter 2021 Financial Results

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial results for the second quarter of 2021."Our successful execution in the second quarter

RHEA-AI

positive

08/03/21 4:10 PM

Nasdaq : DVAX

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 438,000 shares of Dynavax common stock as inducements to 44 newly-hired employees in connection with

RHEA-AI

very positive

07/21/21 4:02 PM

Nasdaq : DVAX

conferencesearnings

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the U.S. financial markets

RHEA-AI

neutral

07/06/21 8:00 AM

Nasdaq : DVAX

covid-19

Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate

Dynavax Technologies Corporation (Dynavax, Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines and Biological E. Limited (BE), a Hyderabad -based vaccine and pharmaceutical company,

RHEA-AI

positive

07/02/21 4:05 PM

Nasdaq : DVAX

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 51,000 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

DVAX Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.dynavax.com
CeoRyan Spencer
Security nameDynavax Technologies Corp.
Issue typecs
SectorManufacturing
Sic code2834
Employees245
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address2100 Powell Street
Address2Suite 900
StateCalifornia
CityEmeryville
Zip94608
CountryUS
Phone15108485100

DVAX Description:

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.